Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to -$3.0 million.

  • Indivior Pharmaceuticals' Cash from Financing Activities rose 9411.76% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 10828.73%. This contributed to the annual value of -$102.0 million for FY2024, which is 5937.5% down from last year.
  • Per Indivior Pharmaceuticals' latest filing, its Cash from Financing Activities stood at -$3.0 million for Q3 2025, which was up 9411.76% from -$5.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Cash from Financing Activities registered a high of $40.0 million during Q4 2024, and its lowest value of -$56.0 million during Q1 2024.
  • Moreover, its 4-year median value for Cash from Financing Activities was -$22.0 million (2023), whereas its average is -$19.8 million.
  • Data for Indivior Pharmaceuticals' Cash from Financing Activities shows a peak YoY increase of 20256.41% (in 2024) and a maximum YoY decrease of 500000.0% (in 2024) over the last 5 years.
  • Indivior Pharmaceuticals' Cash from Financing Activities (Quarter) stood at -$29.0 million in 2022, then crashed by 34.48% to -$39.0 million in 2023, then soared by 202.56% to $40.0 million in 2024, then crashed by 107.5% to -$3.0 million in 2025.
  • Its Cash from Financing Activities stands at -$3.0 million for Q3 2025, versus -$5.0 million for Q2 2025 and -$17.0 million for Q1 2025.